Pyxis Oncology FY 2025 R&D expenses rose 25.45% to USD 74 million, net loss widened to USD 79.62 million

Reuters03-23

<a href="https://laohu8.com/S/PYXS">Pyxis Oncology</a> FY 2025 R&D expenses rose 25.45% to USD 74 million, net loss widened to USD 79.62 million

Pyxis published a press release providing a business update and reporting fourth quarter and full-year 2025 financial results.
Full-year revenue fell 13.9% to USD 13.9 million, while R&D expense rose 25.5% to USD 73.7 million driven by higher contract manufacturing and MICVO clinical trial costs.
Net loss widened 3% to USD 79.6 million, or USD 1.28 per share.
Cash, cash equivalents (including restricted cash) and short-term investments totaled USD 68.3 million, and management said this is expected to fund operations into the fourth quarter of 2026.
Thomas Civik said target enrollment was completed in the Phase 1 MICVO monotherapy dose expansion in 2L+ recurrent/metastatic head and neck squamous cell carcinoma, with updated monotherapy data expected mid-year 2026 and updated MICVO-plus-KEYTRUDA combination data expected in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230700PRIMZONEFULLFEED9676413) on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621777060?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621777060","market":"nz","top_or_hot":-1,"title":"Pyxis Oncology FY 2025 R&D expenses rose 25.45% to USD 74 million, net loss widened to USD 79.62 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PYXS\">Pyxis Oncology</a> FY 2025 R&amp;D expenses rose 25.45% to USD 74 million, net loss widened to USD 79.62 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Pyxis published a press release providing a business update and reporting fourth quarter and full-year 2025 financial results.\n        </li>\n<li>\n          Full-year revenue fell 13.9% to USD 13.9 million, while R&amp;D expense rose 25.5% to USD 73.7 million driven by higher contract manufacturing and MICVO clinical trial costs.\n        </li>\n<li>\n          Net loss widened 3% to USD 79.6 million, or USD 1.28 per share.\n        </li>\n<li>\n          Cash, cash equivalents (including restricted cash) and short-term investments totaled USD 68.3 million, and management said this is expected to fund operations into the fourth quarter of 2026.\n        </li>\n<li>\n          Thomas Civik said target enrollment was completed in the Phase 1 MICVO monotherapy dose expansion in 2L+ recurrent/metastatic head and neck squamous cell carcinoma, with updated monotherapy data expected mid-year 2026 and updated MICVO-plus-KEYTRUDA combination data expected in the second half of 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230700PRIMZONEFULLFEED9676413) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pyxis Oncology FY 2025 R&D expenses rose 25.45% to USD 74 million, net loss widened to USD 79.62 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPyxis Oncology FY 2025 R&D expenses rose 25.45% to USD 74 million, net loss widened to USD 79.62 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 19:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PYXS\">Pyxis Oncology</a> FY 2025 R&amp;D expenses rose 25.45% to USD 74 million, net loss widened to USD 79.62 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Pyxis published a press release providing a business update and reporting fourth quarter and full-year 2025 financial results.\n        </li>\n<li>\n          Full-year revenue fell 13.9% to USD 13.9 million, while R&amp;D expense rose 25.5% to USD 73.7 million driven by higher contract manufacturing and MICVO clinical trial costs.\n        </li>\n<li>\n          Net loss widened 3% to USD 79.6 million, or USD 1.28 per share.\n        </li>\n<li>\n          Cash, cash equivalents (including restricted cash) and short-term investments totaled USD 68.3 million, and management said this is expected to fund operations into the fourth quarter of 2026.\n        </li>\n<li>\n          Thomas Civik said target enrollment was completed in the Phase 1 MICVO monotherapy dose expansion in 2L+ recurrent/metastatic head and neck squamous cell carcinoma, with updated monotherapy data expected mid-year 2026 and updated MICVO-plus-KEYTRUDA combination data expected in the second half of 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230700PRIMZONEFULLFEED9676413) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL5VzGTQ:1","article_id":"2621777060","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621777060","pubTimestamp":1774264062,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pyxis published a press release providing a business update and reporting fourth quarter and full-year 2025 financial results.Full-year revenue fell 13.9% to USD 13.9 million, while R&D expense rose 25.5% to USD 73.7 million driven by higher contract manufacturing and MICVO clinical trial costs.Net loss widened 3% to USD 79.6 million, or USD 1.28 per share.Cash, cash equivalents  and short-term investments totaled USD 68.3 million, and management said this is expected to fund operations into the fourth quarter of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","BK4588":"碎股","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","NDAQ":"纳斯达克OMX交易所","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","PYXS":"Pyxis Oncology, Inc.","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Pyxis Oncology 2025财年研发费用增长25.45%至7400万美元，净亏损扩大至7962万美元","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"PYXS":0.9},"content_text":"Pyxis Oncology FY 2025 R&D expenses rose 25.45% to USD 74 million, net loss widened to USD 79.62 million\n    \n\n\n          Pyxis published a press release providing a business update and reporting fourth quarter and full-year 2025 financial results.\n        \n\n          Full-year revenue fell 13.9% to USD 13.9 million, while R&D expense rose 25.5% to USD 73.7 million driven by higher contract manufacturing and MICVO clinical trial costs.\n        \n\n          Net loss widened 3% to USD 79.6 million, or USD 1.28 per share.\n        \n\n          Cash, cash equivalents (including restricted cash) and short-term investments totaled USD 68.3 million, and management said this is expected to fund operations into the fourth quarter of 2026.\n        \n\n          Thomas Civik said target enrollment was completed in the Phase 1 MICVO monotherapy dose expansion in 2L+ recurrent/metastatic head and neck squamous cell carcinoma, with updated monotherapy data expected mid-year 2026 and updated MICVO-plus-KEYTRUDA combination data expected in the second half of 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230700PRIMZONEFULLFEED9676413) on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621777060","isCrawlerRequest":true}